Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: A randomized trial of 3 vs 4 g/m2 of CY

Bone Marrow Transplantation

Volumn 23, Issue 5, 1999, Pages 421-425

  Weaver, C H ^a   Schwartzberg, L S ^a   Zhen, B ^a   Franco, C ^a   Moore, M ^a   Smith Jr , R ^a   White, L ^a   Van Amburg, A ^a   Hazelton, B ^a   Buckner, C D ^a,b  

^a Clin Res Div Response Oncol I   (United States)

^b Response Oncology Inc   (United States)

Author keywords

Cyclophosphamide; Docetaxel; Mobilization

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; APHERESIS; ARTICLE; BREAST CANCER; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MOBILIZATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033051560     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701599     Document Type: Article

References (34)

1. Ravdin P, Callender N, Hortobagyi G. Registry results and high-dose chemotherapy (letter). J Clin Oncol 1998; 16: 387-388.
2. Lazarus HM. Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions. Cancer Invest 1998; 16: 102-126.
3. Weaver C, Birch R, Schwartzberg L, West W. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. In: Buckner CD, Clift R (eds). Technical and Biological Components of Marrow Transplantation. Kluwer Academic: Boston, MA, 1995, pp 59-85.
4. Antman K, Rowlings P, Vaughan W et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
5. Weaver CH, West WH, Schwartzberg LS et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997; 19: 661-6970.
6. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
7. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide and granulocyte-colony stimulating factor: an analysis of 497 patients. Transfusion 1997; 37: 896-903.
8. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood stem cells following the administration of paclitaxel, cyclophosphamide and filgrastim in patients with breast and ovarian cancer. Biol Blood Marrow Transplant 1997; 3: 83-90.
9. Seidman AD, Hudis CA, Norton L. Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy. Semin Oncol 1995; 22: 3-8.
10. Cortes JE, Pazdur R, Docetaxel. J Clin Oncol 1995;13: 2643-2655.
11. Pazdur R, Newman RA, Newman BM et al. Phase I trial of taxotere: 5-day schedule. J Natl Cancer Inst 1992; 84: 1781-1788.
12. Bissett D, Setanoians A, Cassidy J et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-h infusion. Cancer Res 1993; 53: 523-527.
13. Extra JM, Rousseau F, Bruno R et al. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037-1042.
14. ten Bokkel Huinink WW, Prove AM, Piccart M et al. A phase II trial with docetaxel (taxotere) in second-line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 527-532.
15. Chevallier B, Fumoleau P, Kerbrat P et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-322.
16. Ravdin PM, Burns HAI, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-2885.
17. Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-2894.
18. Schwartzberg L, Birch R, Weaver C et al. Neoadjuvant chemotherapy with or without paclitaxel and high-dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support for locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 1996; 15: 124 (Abstr.).
19. Schwartzberg L, Birch R, Weaver C et al. High pathological complete response (CR) rate to sequential doxorubicin and paclitaxel primary chemotherapy for locally advanced breast cancer (LABC). Proc Annu Meet Am Soc Clin Oncol 1998; 17: 112 (Abstr.).
20. Fennelly D, Schneider J, Spriggs D et al. Dose escalation of paclilaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support. J Clin Oncol 1995; 13: 1160-1166.
21. Demirer T, Rowley S, Buckner CD et al. Peripheral blood stem-cell collections after puclitaxel, cyclophosphamide and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 1995; 13: 1714-1719.
22. Demirer T, Buckner CD, Storer B et al. Effect of different chemotherapy regimens on peripheral blood stem cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 1997; 15: 684-690.
23. Schwartzberg L, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992: I: 317-327.
24. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
25. Weaver CH, Schwartzberg LS, Hainsworth J et al. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997; 19: 671-678.
26. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
27. Weaver CH, Bensinger WI, Appelbaum K et al. Phase I study of high-dose busulfan, melphalan, thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
28. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
29. Haas R, Möhle R, Frühauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
30. Passos-Coelho J, Braine HG, Davis JM et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 1995; 13: 705-714.
31. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
32. Demirer T, Buckner CD, Bensinger WI. Optimization of peripheral blood stem cell mobilization. Stem Cells 1996; 14: 106-116.
33. Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood 1992; 79: 1193-1200.
34. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.